Article

Therapy improves visual field defect

Boston--More than 70% of stroke and traumatic brain injury (TBI) survivors with homonymous visual-field defects demonstrated a visual field improvement of more than 3% following a six-module course of vision restoration therapy, according to a study released by NovaVision.

Boston-More than 70% of stroke and traumatic brain injury (TBI) survivors with homonymous visual-field defects demonstrated a visual field improvement of more than 3% following a six-module course of vision restoration therapy, according to a study released by NovaVision.

The study involved 161 patients from 16 U.S. centers who underwent a 6-month course of the company's Vision Restoration Therapy (VRT). Patients experienced an average 12% improvement in stimulus detection.

Previous studies suggest people who regain 3% improvement or more have functional improvements that may include enhanced quality of life, better reading ability, and the ability to watch television. Functional outcomes were not measured in this study. Age, type of visual-field defect, or the amount of time since the injury did not affect results.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.